162046-56-2

Basic information

• Product Name: 4-[[1-(TERT-BUTOXYCARBONYL)-4-PIPERIDINYL]OXY]BENZOIC ACID
• Synonyms: 1-(tert-Butoxycarbonyl)-4-(4-carboxyphenoxy)piperidine, 4-(4-Carboxyphenoxy)piperidine, N-BOC protected;4-[[1-(TERT-BUTOXYCARBONYL)-4-PIPERIDINYL]OXY]BENZOIC ACID;4-([1-(TERT-BUTOXYCARBONYL)PIPERIDIN-4-YL]OXY)BENZOIC ACID;4-(4-Carboxyphenoxy)piperidine, N-BOC protected;4-(1-Boc-4-piperidyloxy)benzoic acid
• CAS NO: 162046-56-2
• Molecular Formula: C₁₇H₂₃NO₅
• Molecular Weight: 321.37
• Mol File: 162046-56-2.mol
• Article Data: 11

Chemical Properties

• Melting Point: 175 °C
• Boiling Point: 462.325°C at 760 mmHg
• Flash Point: 233.406°C
• Appearance: /
• Density: 1.205g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.548
• Storage Temp.: 2-8°C
• PKA: 4.43±0.10(Predicted)
• CAS DataBase Reference: 4-[[1-(TERT-BUTOXYCARBONYL)-4-PIPERIDINYL]OXY]BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[[1-(TERT-BUTOXYCARBONYL)-4-PIPERIDINYL]OXY]BENZOIC ACID(162046-56-2)
• EPA Substance Registry System: 4-[[1-(TERT-BUTOXYCARBONYL)-4-PIPERIDINYL]OXY]BENZOIC ACID(162046-56-2)

Safety Data

• Hazardous Substances Data: 162046-56-2(Hazardous Substances Data)

Usage

General Description

4-[[1-(tert-butoxycarbonyl)-4-piperidinyl]oxy]benzoic acid is a compound with the chemical formula C21H27NO6. It is a piperidine derivative with a benzoic acid moiety and a tert-butoxycarbonyl (Boc) protecting group. 4-[[1-(TERT-BUTOXYCARBONYL)-4-PIPERIDINYL]OXY]BENZOIC ACID is commonly used as a building block in the synthesis of pharmaceuticals and other organic compounds. The Boc protecting group is often used to temporarily block the reactivity of an amine group, allowing for selective reactions to occur elsewhere in the molecule. Additionally, the piperidine ring confers unique properties to the compound, making it valuable in medicinal chemistry and drug discovery.

InChI:InChI=1/C17H23NO5/c1-17(2,3)23-16(21)18-10-8-14(9-11-18)22-13-6-4-12(5-7-13)15(19)20/h4-7,14H,8-11H2,1-3H3,(H,19,20)

Upstream product

• 118811-07-7 tert-butyl 4-(tosyloxy)piperidin-1-carboxylate 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 281235-00-5 tert-butyl 4-(4-(methoxycarbonyl)phenoxy)piperidine-1-carboxylate 
• 1622206-64-7 C₂₄H₂₉NO₅ 
• 94-18-8 Benzyl 4-hydroxybenzoate 
• 210962-44-0 tert-butyl 4-(4-(ethoxycarbonyl)phenoxy)piperidine-1-carboxylate 

Downstream Products

• 1203600-46-7 tert-butyl 7-[(4-{[1-(tert-butoxycarbonyl)piperidin-4-yl]oxy}benzoyl)oxy]-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1622204-13-0 5-((2-(4-((1-(2-hydroxyethyl)piperidin-4-yl)oxy)benzamide)pyridin-4-yl)oxy)-6-methoxy-N-methyl-1H-indole-1-carboxamide 
• 1622205-37-1 C₂₈H₂₉N₅O₅ 
• 210962-73-5 N-[2-(3-cyanophenoxy)ethyl]-4-(1-tert-butoxycarbonyl-4-piperidyloxy)benzamide 
• 263270-60-6 N-{3-[4-(1-tert-butoxycarbonylpiperidin-4-yloxy)benzamido]-4-methylphenyl}-2-morpholinopyridine-4-carboxamide 
• 250681-89-1 N-[2-methyl-5-(3-morpholinobenzamido)phenyl]-4-(1-tert-butoxycarbonylpiperidin-4-yloxy)benzamide 
• 321337-38-6 tert-butyl 4-(4-(hydroxymethyl)phenoxy)piperidine-1-carboxylate 
• 538335-97-6 methyl 2-acetamido-3-[4-amidino-2-[(2R)-3-ethoxycarbonyl-2-[4-(piperidyl-4-oxy)benzoylamino]propoxy]phenyl]acrylate 

Relevant articles and documents

DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF

Diazanaphthalene compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a diazanaphthalene compound or analogs thereof, in the treatment of disorders characterized by the activa

Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity

A series of chemical optimizations guided by in vitro affinity at a histamine H3 receptor (H3R), physicochemical properties, and pharmacokinetics in rats resulted in identification of N-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride (17v, SUVN-G3031) as a clinical candidate. Compound 17v is a potent (hH3R Ki = 8.73 nM) inverse agonist at H3R with selectivity over other 70 targets, Compound 17v has adequate oral exposures and favorable elimination half-lives both in rats and dogs. It demonstrated high receptor occupancy and marked wake-promoting effects with decreased rapid-eye-movement sleep in orexin-B saporin lesioned rats supporting its potential therapeutic utility in treating human sleep disorders. It had no effect on the locomotor activity at doses several fold higher than its efficacious dose. It is devoid of hERG and phospholipidosis issues. Phase-1 evaluation for safety, tolerability, and pharmacokinetics, and long-term safety studies in animals have been successfully completed without any concern for further development.

Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy

Inhibition of cyclin dependent kinase 2 (CDK2) in complex with cyclin A in G1/S phase of the cell cycle has been shown to promote selective apoptosis of cancer cells through the E2F1 pathway. An alternative approach to catalytic inhibition is to target the substrate recruitment site also known as the cyclin binding groove (CBG) to generate selective non-ATP competitive inhibitors. The REPLACE strategy has been applied to identify fragment alternatives and substituted benzoic acid derivatives were evaluated as a promising scaffold to present appropriate functionality to mimic key peptide determinants. Fragment Ligated Inhibitory Peptides (FLIPs) are described which potently inhibit both CDK2/cyclin A and CDK4/cyclin D1 and have preliminary anti-tumor activity. A structural rationale for binding was obtained through molecular modeling further demonstrating their potential for further development as next generation non ATP competitive CDK inhibitors.